Teva Eyes ‘80% Of Off-Patent Opportunities’ For Generics And Biosimilars

As Israeli Firm Identifies New Long-Term Financial Targets For 2027

 
• By Dean Rudge
Arrows up (Kutsal Lenger/Alamy Stock Photo)
Teva has revealed new five year targets • Source: Shutterstock (Kutsal Lenger / Alamy Stock Phot/Alamy Stock Photo)

More from Strategy

More from Business